Primary retroperitoneal lymph node dissection in clinical stage a non-seminomatous germ cell testis cancer. Review of the Indiana University Experience 1965-1989

J. P. Donohue, J. A. Thornhill, Richard Foster, R. G. Rowland, Richard Bihrle

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

The results of primary retroperitoneal lymph node dissection (RPLND) in 464 patients with clinical stage A non-seminomatous germ cell (NSGC) testis cancer treated over 25 years (1965-1989) were reviewed. The results were analysed in clinical terms and subdivided into early (1965-1978) and contemporary (1979-1989) groups in order to be comparable with series using radiotherapy or surveillance. Between 1965 and 1978 (86 clinical stage A patients) the overall relapse rate of 15% (n = 13) was similar to that of radiotherapy series but survival (97.7% after RPLND) was superior to that achieved with irradiation (87%). From 1979 to 1989, 378 clinical stage A patients had primary RPLND and 30% of them (n = 112) had cancerous nodes. The relapse rate for pathological stage A (n = 266) was 12% and 2 patients died. The relapse rate in pathological stage B patients without adjuvant chemotherapy was 34%. No relapse was seen among 48 pathological stage B patients who received post-operative adjuvant chemotherapy. The death rate was 0.8% among 378 clinical stage A RPLND patients. While not statistically significantly different from death rates reported in current surveillance series, these consistent results spanning 2 eras (before and after cisplatin) over 25 years suggest a sound basis for the surgical approach. The anatomical and medical principles in oncology, which have supported this approach, still remain cogent today. Now that nerve-sparing techniques have been developed, the only long-term morbidity of RPLND (anejaculation) has been avoided. It would seem appropriate to include nerve-sparing RPLND techniques in the management of clinical stage A disease.

Original languageEnglish
Pages (from-to)326-335
Number of pages10
JournalBritish Journal of Urology
Volume71
Issue number3
StatePublished - 1993

Fingerprint

Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
Lymph Node Excision
Recurrence
Adjuvant Chemotherapy
Radiotherapy
Mortality
Cisplatin
Morbidity
Survival

ASJC Scopus subject areas

  • Urology

Cite this

@article{8693b91dd3c0458fb692c60a41422185,
title = "Primary retroperitoneal lymph node dissection in clinical stage a non-seminomatous germ cell testis cancer. Review of the Indiana University Experience 1965-1989",
abstract = "The results of primary retroperitoneal lymph node dissection (RPLND) in 464 patients with clinical stage A non-seminomatous germ cell (NSGC) testis cancer treated over 25 years (1965-1989) were reviewed. The results were analysed in clinical terms and subdivided into early (1965-1978) and contemporary (1979-1989) groups in order to be comparable with series using radiotherapy or surveillance. Between 1965 and 1978 (86 clinical stage A patients) the overall relapse rate of 15{\%} (n = 13) was similar to that of radiotherapy series but survival (97.7{\%} after RPLND) was superior to that achieved with irradiation (87{\%}). From 1979 to 1989, 378 clinical stage A patients had primary RPLND and 30{\%} of them (n = 112) had cancerous nodes. The relapse rate for pathological stage A (n = 266) was 12{\%} and 2 patients died. The relapse rate in pathological stage B patients without adjuvant chemotherapy was 34{\%}. No relapse was seen among 48 pathological stage B patients who received post-operative adjuvant chemotherapy. The death rate was 0.8{\%} among 378 clinical stage A RPLND patients. While not statistically significantly different from death rates reported in current surveillance series, these consistent results spanning 2 eras (before and after cisplatin) over 25 years suggest a sound basis for the surgical approach. The anatomical and medical principles in oncology, which have supported this approach, still remain cogent today. Now that nerve-sparing techniques have been developed, the only long-term morbidity of RPLND (anejaculation) has been avoided. It would seem appropriate to include nerve-sparing RPLND techniques in the management of clinical stage A disease.",
author = "Donohue, {J. P.} and Thornhill, {J. A.} and Richard Foster and Rowland, {R. G.} and Richard Bihrle",
year = "1993",
language = "English",
volume = "71",
pages = "326--335",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Primary retroperitoneal lymph node dissection in clinical stage a non-seminomatous germ cell testis cancer. Review of the Indiana University Experience 1965-1989

AU - Donohue, J. P.

AU - Thornhill, J. A.

AU - Foster, Richard

AU - Rowland, R. G.

AU - Bihrle, Richard

PY - 1993

Y1 - 1993

N2 - The results of primary retroperitoneal lymph node dissection (RPLND) in 464 patients with clinical stage A non-seminomatous germ cell (NSGC) testis cancer treated over 25 years (1965-1989) were reviewed. The results were analysed in clinical terms and subdivided into early (1965-1978) and contemporary (1979-1989) groups in order to be comparable with series using radiotherapy or surveillance. Between 1965 and 1978 (86 clinical stage A patients) the overall relapse rate of 15% (n = 13) was similar to that of radiotherapy series but survival (97.7% after RPLND) was superior to that achieved with irradiation (87%). From 1979 to 1989, 378 clinical stage A patients had primary RPLND and 30% of them (n = 112) had cancerous nodes. The relapse rate for pathological stage A (n = 266) was 12% and 2 patients died. The relapse rate in pathological stage B patients without adjuvant chemotherapy was 34%. No relapse was seen among 48 pathological stage B patients who received post-operative adjuvant chemotherapy. The death rate was 0.8% among 378 clinical stage A RPLND patients. While not statistically significantly different from death rates reported in current surveillance series, these consistent results spanning 2 eras (before and after cisplatin) over 25 years suggest a sound basis for the surgical approach. The anatomical and medical principles in oncology, which have supported this approach, still remain cogent today. Now that nerve-sparing techniques have been developed, the only long-term morbidity of RPLND (anejaculation) has been avoided. It would seem appropriate to include nerve-sparing RPLND techniques in the management of clinical stage A disease.

AB - The results of primary retroperitoneal lymph node dissection (RPLND) in 464 patients with clinical stage A non-seminomatous germ cell (NSGC) testis cancer treated over 25 years (1965-1989) were reviewed. The results were analysed in clinical terms and subdivided into early (1965-1978) and contemporary (1979-1989) groups in order to be comparable with series using radiotherapy or surveillance. Between 1965 and 1978 (86 clinical stage A patients) the overall relapse rate of 15% (n = 13) was similar to that of radiotherapy series but survival (97.7% after RPLND) was superior to that achieved with irradiation (87%). From 1979 to 1989, 378 clinical stage A patients had primary RPLND and 30% of them (n = 112) had cancerous nodes. The relapse rate for pathological stage A (n = 266) was 12% and 2 patients died. The relapse rate in pathological stage B patients without adjuvant chemotherapy was 34%. No relapse was seen among 48 pathological stage B patients who received post-operative adjuvant chemotherapy. The death rate was 0.8% among 378 clinical stage A RPLND patients. While not statistically significantly different from death rates reported in current surveillance series, these consistent results spanning 2 eras (before and after cisplatin) over 25 years suggest a sound basis for the surgical approach. The anatomical and medical principles in oncology, which have supported this approach, still remain cogent today. Now that nerve-sparing techniques have been developed, the only long-term morbidity of RPLND (anejaculation) has been avoided. It would seem appropriate to include nerve-sparing RPLND techniques in the management of clinical stage A disease.

UR - http://www.scopus.com/inward/record.url?scp=0027522454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027522454&partnerID=8YFLogxK

M3 - Article

C2 - 8386580

AN - SCOPUS:0027522454

VL - 71

SP - 326

EP - 335

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 3

ER -